推荐产品
产品名称
Discovery ® C8 HPLC 色谱柱, 5 μm particle size, L × I.D. 25 cm × 4.6 mm
物料
stainless steel column
质量水平
Agency
suitable for USP L7
产品线
Discovery®
特点
endcapped
制造商/商品名称
Discovery®
包装
1 ea of
标记范围
7.5% Carbon loading
参数
≤70 °C temp. range
400 bar pressure (5801 psi)
技术
HPLC: suitable
LC/MS: suitable
长度 × 内径
25 cm × 4.6 mm
表面积
200 m2/g
表面覆盖度
3.4 μmol/m2
杂质
<10 ppm metals
基质
silica gel, high purity, spherical base material
fully porous particle
基质活性基团
C8 (octyl) phase
粒径
5 μm
孔径
180 Å
工作pH范围
2-8
应用
food and beverages
分离技术
reversed phase
正在寻找类似产品? 访问 产品对比指南
应用
Discovery® C8 HPLC 色谱柱可用于通过固相微萃取（SPME）和之后的高效液相色谱-串联质谱（HPLC-MS / MS）联用法测定包括尿液、培养物和组织在内的生物基质中的双酚A、染料木黄酮、双酚A β-D-葡萄糖醛酸 (BPA gluc) 和染料木黄酮4′-β-D-葡萄糖醛酸 (genistein gluc)。
特点和优势
- 优良的重现性。
- 分析强疏水性化合物时比 C18 柱快
- 稳定性好、低流失，适用于 LC-MS 分析
- 分析碱性和酸性化合物均可获得良好峰形
- 可兼容低有机溶剂/高含水量的流动相
法律信息
Discovery is a registered trademark of Merck KGaA, Darmstadt, Germany
Measurement of bisphenol A, bisphenol A β-d-glucuronide, genistein, and genistein 4′- β-d-glucuronide via SPE and HPLC-MS/MS.
Coughlin LJ, et al.
Analytical and Bioanalytical Chemistry, 401, 995-1002 (2011)
M Q Zhang et al.
Die Pharmazie, 46(10), 687-700 (1991-10-01)
The rapid growth in the quinolone research changed the whole face of the previous SAR concepts. So far structural modifications at all positions of the quinolone nucleus except the 4-oxo group have successfully lead to the discovery of potent antimicrobial
G L Bundy et al.
The Journal of biological chemistry, 261(2), 747-751 (1986-01-15)
The gorgonian coral Pseudoplexaura porosa contains a lipoxygenase capable of converting exogenous arachidonic acid into (8R)-8-hydroperoxy-5,9,11,14-eicosatetraenoic acid. The (8R)- (or 8-L-) configuration in this product, opposite to that observed in previously reported 8-lipoxygenase products, was determined unambiguously by comparison of
Hugo M Botelho et al.
Scientific reports, 5, 9038-9038 (2015-03-13)
Plasma membrane proteins are essential molecules in the cell which mediate interactions with the exterior milieu, thus representing key drug targets for present pharma. Not surprisingly, protein traffic disorders include a large range of diseases sharing the common mechanism of
Scott C Bell et al.
Pharmacology & therapeutics, 145, 19-34 (2014-06-17)
With the discovery of the CFTR gene in 1989, the search for therapies to improve the basic defects of cystic fibrosis (CF) commenced. Pharmacological manipulation provides the opportunity to enhance CF transmembrane conductance regulator (CFTR) protein synthesis and/or function. CFTR
相关内容
Discovery C18 and C8 HPLC Columns products offered
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门